RNXT — RenovoRx, Inc.
—
Nasdaq ·
Health Care ·
Health Care Equipment & Supplies ·
CIK 1574094 ·
Last close
$1.66
Market Cap
$74.91M
52W High
$2.59
52W Low
$0.70
ADV30
1,225,380
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 909,000 | 766,000 | -3,349,000 | -2,911,000 | 11,472,000 | 9,479,000 | 2,493,000 |
| Mar 2026 | 563,000 | 479,000 | -3,469,000 | -3,521,000 | 13,964,000 | 12,362,000 | 2,699,000 |
| Dec 2025 | 238,000 | 210,000 | -3,523,000 | -2,941,000 | 8,095,000 | 7,024,000 | 2,673,000 |
| Sep 2025 | 266,000 | 213,000 | -3,200,000 | -2,912,000 | 11,206,000 | 10,044,000 | 3,128,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-11,301,000
Investing CF
$0
Financing CF
$9,081,000
CapEx
$-2,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.33
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-64,908,000
Inventory
$379,000
Receivables
$280,000
ST Investments
—
EBIT TTM
$-12,870,000
Pretax Income TTM
$-12,270,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,976,000
EBITDA
$-13,034,000
Free Cash Flow
$-6,648,000
Enterprise Value
$70,338,936
Total Cash
$9,479,000
Total Debt
$390,000
Shares Out
45,129,508
Trailing EPS
$-0.31
Book Value
$0.20
ROE
-125.2%
ROA
-64.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,123,000 | -12,511,000 | -11,168,000 | 8,095,000 | 2,673,000 | 5,422,000 | -10,973,000 |
| Dec 2024 | 43,000 | -10,970,000 | -8,814,000 | 8,118,000 | 3,640,000 | 4,478,000 | -9,125,000 |
| Dec 2023 | 0 | -11,396,000 | -10,232,000 | 1,466,000 | 4,466,000 | -3,000,000 | -10,258,000 |
| Dec 2022 | 0 | -9,950,000 | -9,889,000 | 7,265,000 | 1,102,000 | 6,163,000 | -8,811,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.12
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RTGN | RetinalGenix Technologies Inc. | $75.19M | $3.99 | — |
| HYPR | Hyperfine, Inc. | $73.98M | $0.81 | — |
| GUTS | FRACTYL HEALTH, INC. | $77.36M | $0.49 | — |
| CVRX | CVRx, Inc. | $71.93M | $2.70 | — |
| STEX | Streamex Corp. | $81.53M | $0.70 | — |
News headlines (Yahoo Finance, 1h cache)
RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline
2026-09-02 14:39 · Yahoo
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
2026-08-25 12:30 · Yahoo
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
2026-08-21 12:30 · Yahoo
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers
2026-08-17 01:01 · Yahoo
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ...
2026-08-13 05:02 · Yahoo
RenovoRx Q2 Earnings Call Highlights
2026-08-13 02:04 · Yahoo
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
2026-08-12 22:15 · Yahoo
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
2026-08-11 12:30 · Yahoo
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors
2026-08-06 12:30 · Yahoo
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th
2026-08-04 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.